Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin’s lymphoma in patients older than 50 years

Martı́nez, Carmen; Jorge, Ana; Pereira, Arturo; Moreno, Miriam; Núñez, J.; Gayoso, Jorge; González-Medina, José; Revilla, Nuria; Sampol, Antònia; Domingo‐Domenech, Eva; Cruz, Fátima De la; Morales, Álvaro; Rodríguez-Salazar, Maria J.; Valiente, S.; Pérez‐Ceballos, Elena; Oteyza, Jaime Pérez de

doi:10.1007/s00277-016-2832-6

Cited by 16 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, although older age alone does not negatively affect overall survival after AHSCT for lymphoma 79 , in the treatment of MS, the evidence provides the strongest rationale for AHSCT in young patients (aged <45 years) with a short disease duration (<10 years).…”

Section: [H3] Age and Duration Of Diseasementioning

confidence: 99%

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

et al. 2017

View full text Add to dashboard Cite

Autologous haematopoietic stem cell transplantation (AHSCT) is a multistep procedure that enables destruction of the immune system and its reconstitution from haematopoietic stem cells. Originally developed for the treatment of haematological malignancies, the procedure has been adapted for the treatment of severe immune-mediated disorders. Results from ~20 years of research make a compelling case for selective use of AHSCT in patients with highly active multiple sclerosis (MS), and for controlled trials. Immunological studies support the notion that AHSCT causes qualitative immune resetting, and have provided insight into the mechanisms that might underlie the powerful treatment effects that last well beyond recovery of immune cell numbers. Indeed, studies have demonstrated that AHSCT can entirely suppress MS disease activity for 4–5 years in 70–80% of patients, a rate that is higher than those achieved with any other therapies for MS. Treatment-related mortality, which was 3.6% in studies before 2005, has decreased to 0.3% in studies since 2005. Current evidence indicates that the patients who are most likely to benefit from and tolerate AHSCT are young, ambulatory and have inflammatory MS activity. Clinical trials are required to rigorously test the efficacy, safety and cost-effectiveness of AHSCT against highly active MS drugs

show abstract

Section: [H3] Age and Duration Of Diseasementioning

confidence: 99%

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although the impact of the diagnosis (MM, different type of lymphomas) was not directly compared, generally patients with NHL showed slightly higher NRM rates than Hodgkin lymphoma and clear significant increased risk compared with MM [9,11,17,21]. Other variables were tested, such as chemotherapy lines before transplant or disease status, but no clear association was found.…”

Section: Discussionmentioning

confidence: 99%

Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score

Berro

Chhabra

Piñana

et al. 2020

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Biology of Blood and Marrow Transplantationjournal homepage : www.bbmt.org (day 100: 1.5% versus 2.4% versus 7.6% versus 17.6%) as well as long term (1 to 3 years; 1.8% to 2.3% versus 3.8% to 4.9% versus 11.7% to 14.5% versus 25.0% to 27.4%, respectively; P< .0001) and OS (1 to 5 years; 94% to 73% versus 89% to 75% versus 76% to 47% versus 65% to 52% respectively; P < .0001). The score was validated in an independent cohort (N = 2168) and was significantly associated with early and late events. In conclusion, we developed and validated a novel score predicting NRM and OS in 2 large cohorts of more than 2000 autologous transplant patients. This tool can be useful for tailoring conditioning regimens or defining risk for transplant program decision making.

show abstract

“…Initial steps in this direction have been taken by various workgroups in the case of relapsing tumors of different entities. So, the group of Martinez could show that in the case of relapsed Hodgkin`s lymphoma in patients older than 50 years, a CCI > 1 is associated with poor OS and progression-free survival, independently of age [14]. Other publications that cover relapsing neck cancer have produced similar results: If the frequency or severity of comorbidity increases, survival progressively decreases [15,16].…”

Section: Introductionmentioning

confidence: 88%

Age-Adjusted Charlson Comorbidity Index in Recurrent Glioblastoma: A New Prognostic Factor?

Barz

Bette

Janssen

et al. 2020

Preprint

View full text Add to dashboard Cite

Backround: For recurrent glioblastoma (GB) patients, several therapy options have been established over the last years such as more aggressive surgery, re-irradiation or chemotherapy. Age and the Karnofsky Performance Status Scale (KPSS) are used to make decisions for these patients as these are established as prognostic factors in the initial diagnosis of GB. This study’s aim was to evaluate preoperative patient comorbidities by using the age-adjusted Charlson Comorbidity Index (ACCI) as a prognostic factor for recurrent GB patients.Methods: In this retrospective analysis we could include 133 patients with surgery for primary recurrence of GB from January 2007 until December 2016 (49 females, 84 males, mean age 58 years (range 21–80 years)). Preoperative age, sex, ACCI, KPSS and adjuvant treatment regimes were recorded for each patient. Extent of resection (EOR) was recorded as a complete/incomplete (including biopsy) resection of the contrast-enhancing tumor part.Results: Median overall survival (OS) after initial diagnosis was 20.0 months (95% confidence interval (CI) 17.2-22.9)) and 9.0 months (95% CI 7.1-10.9 months) after first re-resection. Preoperative KPSS > 80% (P<0.001) and ACCI <7 (P=0.020) were associated with significantly improved survival in univariate analysis. Including these preoperative factors in multivariate analysis, preoperative KPSS (≥80/<80) is the only significant prognostic factor (HR 1.934[1.3-3.0], P=0.003), whereas ACCI (<7/≥7) missed statistical significance (HR 1.608[0.8-3.1], P=0.154). Conclusion: ACCI might be an additional prognostic factor for patients with recurrent glioblastoma, especially in those with many comorbidities. However, besides the well-established KPSS, the ACCI does not add further information about patients’ prognosis.

show abstract

Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin’s lymphoma in patients older than 50 years

Cited by 16 publications

References 22 publications

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score

Age-Adjusted Charlson Comorbidity Index in Recurrent Glioblastoma: A New Prognostic Factor?

Contact Info

Product

Resources

About